dc.contributor.author | Tiong, IS | |
dc.contributor.author | Dillon, R | |
dc.contributor.author | Ivey, A | |
dc.contributor.author | Teh, T-C | |
dc.contributor.author | Nguyen, P | |
dc.contributor.author | Cummings, N | |
dc.contributor.author | Taussig, DC | |
dc.contributor.author | Latif, A-L | |
dc.contributor.author | Potter, NE | |
dc.contributor.author | Runglall, M | |
dc.contributor.author | Russell, NH | |
dc.contributor.author | Raj, K | |
dc.contributor.author | Schwarer, AP | |
dc.contributor.author | Fong, CY | |
dc.contributor.author | Grigg, AP | |
dc.contributor.author | Wei, AH | |
dc.date.accessioned | 2022-05-09T14:48:49Z | |
dc.date.available | 2022-05-09T14:48:49Z | |
dc.identifier.citation | British journal of haematology, 2021, 192 (6), pp. 1026 - 1030 | en |
dc.identifier.issn | 0007-1048 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5118 | |
dc.identifier.eissn | 1365-2141 | en_US |
dc.identifier.eissn | 1365-2141 | |
dc.identifier.doi | 10.1111/bjh.16722 | en_US |
dc.identifier.doi | 10.1111/bjh.16722 | |
dc.description.abstract | Based on promising results in older adults with acute myeloid leukaemia (AML), we treated patients with NPM1<sup>mut</sup> measurable residual disease (MRD) using off-label venetoclax in combination with low-dose cytarabine or azacitidine. Twelve consecutive patients were retrospectively identified, including five with molecular persistence and seven with molecular relapse/progression. All patients with molecular persistence achieved durable molecular complete remission (CR<sub>MRD-</sub> ) without transplantation. Six of seven patients with molecular relapse/progression achieved CR<sub>MRD-</sub> after 1-2 cycles of venetoclax. This paper highlights the promising efficacy of venetoclax-based therapy to reduce the relapse risk in patients with persistent or rising NPM1<sup>mut</sup> MRD. | en_US |
dc.format | Print-Electronic | en_US |
dc.format.extent | 1026 - 1030 | en_US |
dc.language | eng | en_US |
dc.language.iso | eng | en |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | en |
dc.subject | Humans | en_US |
dc.subject | Neoplasm, Residual | en_US |
dc.subject | Sulfonamides | en_US |
dc.subject | Neoplasm Proteins | en_US |
dc.subject | Nuclear Proteins | en_US |
dc.subject | Retrospective Studies | en_US |
dc.subject | Mutation | en_US |
dc.subject | Adult | en_US |
dc.subject | Aged | en_US |
dc.subject | Aged, 80 and over | en_US |
dc.subject | Middle Aged | en_US |
dc.subject | Female | en_US |
dc.subject | Male | en_US |
dc.subject | Leukemia, Myeloid, Acute | en_US |
dc.subject | Bridged Bicyclo Compounds, Heterocyclic | en_US |
dc.subject | Nucleophosmin | en_US |
dc.title | Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia. | en |
dc.type | Journal Article | |
dcterms.dateAccepted | 2020-04-14 | |
rioxxterms.version | VoR | en |
rioxxterms.versionofrecord | 10.1111/bjh.16722 | en |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by-nc/4.0 | en |
dc.relation.isPartOf | British journal of haematology | en_US |
pubs.issue | 6 | en_US |
pubs.notes | Not known | en_US |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Acute Leukaemia | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Acute Leukaemia/Acute Leukaemia (hon.) | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | en_US |
pubs.volume | 192 | en_US |
pubs.embargo.terms | Not known | en_US |
icr.researchteam | Acute Leukaemia | |
dc.contributor.icrauthor | Taussig, David | |